Condition: Mantle Cell Lymphoma · Sponsor: University College, London
Phase II, multicentre, randomised, open-label study to assess the benefit of early intervention with fixed duration, time-limited zanubrutinib-rituximab in indolent mantle cell lymphoma (MCL)
This description comes directly from the study's public registry record.
ZEBRA Trial Manager · (+44) (0)2076799860 · ctc.zebra@ucl.ac.uk
Always discuss trial participation with your own doctor first.
| Royal Derby Hospital | Derby, United Kingdom | Recruiting |
| Beatson West of Scotland Cancer Centre | Glasgow, United Kingdom | Recruiting |
| Clatterbridge Cancer Centre | Liverpool, United Kingdom | Recruiting |
| Guy's Hospital | London, United Kingdom | Recruiting |
| St Bartholomew's Hospital | London, United Kingdom | Recruiting |
| University College London Hospital | London, United Kingdom | Recruiting |
| Christie Hospital | Manchester, United Kingdom | Recruiting |
| Norfolk and Norwich University Hospitl | Norwich, United Kingdom | Recruiting |
| Nottingham City Hospital | Nottingham, United Kingdom | Recruiting |
| Churchill Hospital | Oxford, United Kingdom | Recruiting |
| Derriford Hospital | Plymouth, United Kingdom | Recruiting |
| Southampton General Hospital | Southampton, United Kingdom | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05635162